home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3223.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
39 lines
Document 3223
DOCN M94A3223
TI Effects on virological parameters of passive immunotherapy in AIDS
patients. The PI Collaborative Study Group.
DT 9412
AU Joubert L; Chevret S; Vittecoq D; Lefrere JJ; Hopital St-Antoine, Paris.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):125 (abstract no. PA0118). Unique
Identifier : AIDSLINE ICA10/94369352
AB Eighty two CDC IV patients were evaluated in a double blind phase II
trial and randomized between 2 groups: infusions of plasma rich in
anti-p24 ab (HIV+P) or seronegative plasma (HIV-P). Each patient
received infusion every 14 days over a one-year period and every 28 days
beyond; p24 ag titer was quantified through monoclonal assay before and
after immune complex dissociation (ICD). Anti-p24 ab titer was
determined. Among the 46 patients positive for p24 ag before inclusion,
p24 ag was found negative in 100% of treated patients in a median delay
of 77 days, vs in 24% of controls in a median delay not reached at 1091
days (p = 0.0001). The reapparance of a positive p24 ag was less
frequent in treated patients (24%) than in controls (33%) (p = 0.31);
among the 54 patients positive for ICD-p24, p24 ag was found negative in
52% of treated patients in a median delay of 310 days vs 17% of controls
(median not reached) (p = 0.006). Anti-p24 titers were negative or weak
in most controls while treated patients had a titer variable according
to both the ab titer of HIV+P and the ag of recipients. The negative p24
ag without ICD observed in all treated patients reflects a complexation
with ab; the results observed with ICD-ag assay suggest that this
decrease of ag in treated group could also be due to a slower release of
ag.
DE Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*MICROBIOLOGY/ *THERAPY
Comparative Study Double-Blind Method Human HIV
Antibodies/TOXICITY/*THERAPEUTIC USE HIV Core Protein
p24/BLOOD/IMMUNOLOGY *Immunotherapy, Adoptive/ADVERSE EFFECTS CLINICAL
TRIAL CLINICAL TRIAL, PHASE II MEETING ABSTRACT RANDOMIZED CONTROLLED
TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).